Malignant pleural effusion is seen in up to 15 percent of all cancer patients.

Ipsilateral pleural involvement is seen in 90 percent of cases of lung cancer.

Pleural effusion in ovarian cancer may represent a comparatively better prognosis when compared to other tumors. Fifteen percent of patients may present with the wet pleural disease as the first sign of cancer.

While 20 percent of patients with Hodgkin’s lymphoma may present with MPE at the time of diagnosis, effusions may represent a disease progression in around 60 percent of patients. It is associated with a poor prognosis and may represent chemotherapy-resistant disease.

Both infiltrations of the pleural space and tumor-immune cell interactions in the pleural microenvironment represent underlying pathophysiologic mechanisms.